You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: April 8, 2020

DrugPatentWatch Database Preview

Hetero Labs Ltd Iii Company Profile

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for HETERO LABS LTD III, and what generic and branded alternatives to HETERO LABS LTD III drugs are available?

HETERO LABS LTD III has thirty-nine approved drugs.

There are five tentative approvals on HETERO LABS LTD III drugs.

Summary for Hetero Labs Ltd Iii
US Patents:0

Drugs and US Patents for Hetero Labs Ltd Iii

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hetero Labs Ltd Iii TORSEMIDE torsemide TABLET;ORAL 079234-004 Jan 27, 2009 AB RX No No   Start Trial   Start Trial
Hetero Labs Ltd Iii SIMVASTATIN simvastatin TABLET;ORAL 200895-004 Nov 25, 2014 AB RX No No   Start Trial   Start Trial
Hetero Labs Ltd Iii LEVETIRACETAM levetiracetam SOLUTION;ORAL 203052-001 Feb 28, 2013 AA RX No No   Start Trial   Start Trial
Hetero Labs Ltd Iii TADALAFIL tadalafil TABLET;ORAL 209908-002 Mar 26, 2019 AB RX No No   Start Trial   Start Trial
Hetero Labs Ltd Iii HYDROXYZINE HYDROCHLORIDE hydroxyzine hydrochloride TABLET;ORAL 040805-003 May 29, 2008 AB RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for HETERO LABS LTD III drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.